Kiniksa Pharmaceuticals International, plc Class A Share Price

Kiniksa Pharmaceuticals International, plc Class A Share Price

NASDAQ: KNSA | Mid Cap
$96.39
+$1.41 (1.48%) Last updated on 29 Oct, 2026 | 20:39 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Kiniksa Pharmaceuticals International, plc Class A Stock Performance

Open
$94.51
Prev. Close
$94.98
Circuit Range
N/A
Day Range
$94.51 - $96.94
Year Range
$36.61 - $96.94
Volume
23,502
Average Traded
$95.81

Kiniksa Pharmaceuticals International, plc Class A Share Price Today

As of 29 October 2026, Kiniksa Pharmaceuticals International, plc Class A's share price is $96.39. The stock opened at $94.51, compared to its previous close of $94.98. During today's trading session, Kiniksa Pharmaceuticals International, plc Class A's share price traded between $94.51 and $96.94, with an average price of $95.73. Over the past 52 weeks, the stock has recorded a high of $96.94 and a low of $36.61. In terms of performance, Kiniksa Pharmaceuticals International, plc Class A's share price has risen by 79.36% over the last six months and is up 160.80% on a year-on-year basis.

Kiniksa Pharmaceuticals International, plc Class A Share Price Chart

Line chart of the Kiniksa Pharmaceuticals International, plc Class A price trend over the selected period. The price rose overall, ranging from 94.46 to 96.67, ending at 96.39.
$94.51$96.94
L
Show Current Price
H

Kiniksa Pharmaceuticals International, plc Class A Stock Fundamentals & Key Indicators

Market Cap
$7.15B
PE Ratio (TTM)
63.52
Dividend Yield
0.00%
EPS (TTM)
$1.40
Revenue (TTM)
$677.56B
Return On Equity (TTM)
15.43%
Profit Margin
8.71%
Debt to Equity
0.15
Quarterly Earnings Growth YoY
233.45%

Kiniksa Pharmaceuticals International, plc Class A Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$202.13$214.27$243.60$285.97
Net Profit$14.20$22.59$25.43$47.35
Net Profit Margin7.03%10.54%10.44%16.56%
Income ChangeN/A59.08%12.57%86.20%

Kiniksa Pharmaceuticals International, plc Class A Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$220.18$270.26$423.24$677.56
Net Profit$183.36$14.08-$43.19$59.01
Net Profit Margin83.28%5.21%-10.20%8.71%
Income ChangeN/A-92.32%-406.75%236.63%

About Kiniksa Pharmaceuticals International, plc Class A

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Kiniksa Pharmaceuticals International, plc Class A Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$73.87
$95.63
+28.09%
Sep 2026
$78.93
$74.66
-6.34%
Aug 2026
$73.19
$79.71
+7.14%
Jul 2026
$63.51
$74.40
+16.40%
Jun 2026
$47.66
$63.92
+32.09%
May 2026
$53.38
$48.39
-9.96%
Apr 2026
$48.90
$53.74
+11.29%
Mar 2026
$44.13
$48.29
+8.50%
Feb 2026
$43.84
$44.51
+1.40%
Jan 2026
$41.50
$43.89
+6.58%
Dec 2025
$42.39
$41.18
-3.08%
Nov 2025
$37.48
$42.49
+14.96%

KNSA Share Price FAQs